These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
305 related articles for article (PubMed ID: 33579785)
1. Identification and Therapeutic Targeting of GPR20, Selectively Expressed in Gastrointestinal Stromal Tumors, with DS-6157a, a First-in-Class Antibody-Drug Conjugate. Iida K; Abdelhamid Ahmed AH; Nagatsuma AK; Shibutani T; Yasuda S; Kitamura M; Hattori C; Abe M; Hasegawa J; Iguchi T; Karibe T; Nakada T; Inaki K; Kamei R; Abe Y; Nomura T; Andersen JL; Santagata S; Hemming ML; George S; Doi T; Ochiai A; Demetri GD; Agatsuma T Cancer Discov; 2021 Jun; 11(6):1508-1523. PubMed ID: 33579785 [TBL] [Abstract][Full Text] [Related]
2. A Phase I, Multicenter, Open-Label, First-in-Human Study of DS-6157a in Patients with Advanced Gastrointestinal Stromal Tumor. George S; Heinrich MC; Somaiah N; Oppelt P; McLeod R; Nishioka S; Kundu MG; Qian X; Kumar P; Laadem A; Lau Y; Tran BP; Fallon M; Dosunmu O; Shi J; Naito Y Clin Cancer Res; 2023 Sep; 29(18):3659-3667. PubMed ID: 37363962 [TBL] [Abstract][Full Text] [Related]
3. Clinical efficacy of second-generation tyrosine kinase inhibitors in imatinib-resistant gastrointestinal stromal tumors: a meta-analysis of recent clinical trials. Wu L; Zhang Z; Yao H; Liu K; Wen Y; Xiong L Drug Des Devel Ther; 2014; 8():2061-7. PubMed ID: 25378911 [TBL] [Abstract][Full Text] [Related]
4. Phase I Study of Rapid Alternation of Sunitinib and Regorafenib for the Treatment of Tyrosine Kinase Inhibitor Refractory Gastrointestinal Stromal Tumors. Serrano C; Leal A; Kuang Y; Morgan JA; Barysauskas CM; Phallen J; Triplett O; Mariño-Enríquez A; Wagner AJ; Demetri GD; Velculescu VE; Paweletz CP; Fletcher JA; George S Clin Cancer Res; 2019 Dec; 25(24):7287-7293. PubMed ID: 31471313 [TBL] [Abstract][Full Text] [Related]
5. Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors. Zeng C; Zhu L; Jia X; Pang Y; Li Z; Lu X; Xie F; Duan L; Wang Y Gastric Cancer; 2020 Sep; 23(5):837-847. PubMed ID: 32291709 [TBL] [Abstract][Full Text] [Related]
6. Novel Insights into the Treatment of Imatinib-Resistant Gastrointestinal Stromal Tumors. Serrano C; George S; Valverde C; Olivares D; García-Valverde A; Suárez C; Morales-Barrera R; Carles J Target Oncol; 2017 Jun; 12(3):277-288. PubMed ID: 28478525 [TBL] [Abstract][Full Text] [Related]
7. Emerging drugs for the treatment of gastrointestinal stromal tumors. Pilco-Janeta DF; García-Valverde A; Gomez-Peregrina D; Serrano C Expert Opin Emerg Drugs; 2021 Mar; 26(1):53-62. PubMed ID: 33645383 [TBL] [Abstract][Full Text] [Related]
8. Systemic therapy of advanced/metastatic gastrointestinal stromal tumors: an update on progress beyond imatinib, sunitinib, and regorafenib. Mohammadi M; Gelderblom H Expert Opin Investig Drugs; 2021 Feb; 30(2):143-152. PubMed ID: 33252274 [No Abstract] [Full Text] [Related]
10. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients. Garner AP; Gozgit JM; Anjum R; Vodala S; Schrock A; Zhou T; Serrano C; Eilers G; Zhu M; Ketzer J; Wardwell S; Ning Y; Song Y; Kohlmann A; Wang F; Clackson T; Heinrich MC; Fletcher JA; Bauer S; Rivera VM Clin Cancer Res; 2014 Nov; 20(22):5745-5755. PubMed ID: 25239608 [TBL] [Abstract][Full Text] [Related]
11. Tyrosine kinase inhibitors in the treatment of unresectable or metastatic gastrointestinal stromal tumors. Nishida T; Doi T; Naito Y Expert Opin Pharmacother; 2014 Oct; 15(14):1979-89. PubMed ID: 24990162 [TBL] [Abstract][Full Text] [Related]
12. [The importance of mutational status in prognosis and therapy of GIST]. Comandone A; Boglione A Recenti Prog Med; 2015 Jan; 106(1):17-22. PubMed ID: 25621775 [TBL] [Abstract][Full Text] [Related]
13. Emerging drugs for the treatment of gastrointestinal stromal tumour. Kasireddy V; von Mehren M Expert Opin Emerg Drugs; 2017 Dec; 22(4):317-329. PubMed ID: 29183145 [TBL] [Abstract][Full Text] [Related]
14. Dual Targeting of Insulin Receptor and KIT in Imatinib-Resistant Gastrointestinal Stromal Tumors. Chen W; Kuang Y; Qiu HB; Cao Z; Tu Y; Sheng Q; Eilers G; He Q; Li HL; Zhu M; Wang Y; Zhang R; Wu Y; Meng F; Fletcher JA; Ou WB Cancer Res; 2017 Sep; 77(18):5107-5117. PubMed ID: 28760855 [TBL] [Abstract][Full Text] [Related]
15. Robust Activity of Avapritinib, Potent and Highly Selective Inhibitor of Mutated KIT, in Patient-derived Xenograft Models of Gastrointestinal Stromal Tumors. Gebreyohannes YK; Wozniak A; Zhai ME; Wellens J; Cornillie J; Vanleeuw U; Evans E; Gardino AK; Lengauer C; Debiec-Rychter M; Sciot R; Schöffski P Clin Cancer Res; 2019 Jan; 25(2):609-618. PubMed ID: 30274985 [TBL] [Abstract][Full Text] [Related]
16. A novel anti-c-Kit antibody-drug conjugate to treat wild-type and activating-mutant c-Kit-positive tumors. Kim JO; Kim KH; Baek EJ; Park B; So MK; Ko BJ; Ko HJ; Park SG Mol Oncol; 2022 Mar; 16(6):1290-1308. PubMed ID: 34407310 [TBL] [Abstract][Full Text] [Related]
17. The safety of regorafenib for the treatment of gastrointestinal stromal tumors. Rutkowski P; Stępniak J Expert Opin Drug Saf; 2016 Jan; 15(1):105-16. PubMed ID: 26651387 [TBL] [Abstract][Full Text] [Related]
18. Integrated Screens Identify CDK1 as a Therapeutic Target in Advanced Gastrointestinal Stromal Tumors. Lu X; Pang Y; Cao H; Liu X; Tu L; Shen Y; Jia X; Lee JC; Wang Y Cancer Res; 2021 May; 81(9):2481-2494. PubMed ID: 33727226 [TBL] [Abstract][Full Text] [Related]
19. [Medical treatment for gastrointestinal stromal tumor (GIST) in Japan]. Sato A; Hamada K; Imataka H Gan To Kagaku Ryoho; 2012 May; 39(5):708-12. PubMed ID: 22584320 [TBL] [Abstract][Full Text] [Related]
20. Activity and safety of the multi-target tyrosine kinase inhibitor cabozantinib in patients with metastatic gastrointestinal stromal tumour after treatment with imatinib and sunitinib: European Organisation for Research and Treatment of Cancer phase II trial 1317 'CaboGIST'. Schöffski P; Mir O; Kasper B; Papai Z; Blay JY; Italiano A; Benson C; Kopeckova K; Ali N; Dileo P; LeCesne A; Menge F; Cousin S; Wardelmann E; Wozniak A; Marreaud S; Litiere S; Zaffaroni F; Nzokirantevye A; Vanden Bempt I; Gelderblom H Eur J Cancer; 2020 Jul; 134():62-74. PubMed ID: 32470848 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]